Mesh Bio, a Singapore-based health deep tech startup, announced Thursday that it had raised an undisclosed amount of funding from East Ventures, a venture capital firm focusing on Southeast Asia.
Mesh Bio said in a statement that the funding will be allocated to further develop the digital twin technologies in chronic disease management and to expand its services across Southeast Asia, mainly Indonesia, Malaysia, and the Philippines.
“Given the increasing aging population worldwide, Mesh Bio has consistently prioritized the development of innovative solutions to alleviate healthcare challenges associated with chronic diseases,
“We are glad to receive the support from East Ventures, and we are confident that this funding will serve as a strong foundation in our vision to confront the rising burden of chronic diseases across the regions,” said Dr. Andrew Wu, Co-Founder and Chief Executive Officer of Mesh Bio.
Founded in 2018 by Andrew Wu (Co-Founder and Chief Executive Officer) and Arsen Batagov (Co-Founder and Chief Technology Officer), Mesh Bio is a digital health startup focused on addressing the growing global clinical burden of metabolic diseases due to aging population, and challenges in care delivery.
The firm develops clinical decision support analytics and automation solutions for management of chronic disease, such as cardiovascular disease.
These solutions enable data driven care delivery, improving patient engagement, and health outcomes.
Mesh Bio said that the firm has the vision to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region.
According to the statement, noncommunicable diseases (NCDs) or chronic diseases, such as cardiovascular diseases and diabetes, impose a major and growing burden on health and development in the Southeast Asia region.
It noted that in the region, 62 percent of all deaths are due to NCDs, accounting for 9 million persons.
It said the increase in chronic diseases leads to complex and challenging patient management.
It also said the situation is compounded by the lack of doctors, especially specialists, so that general practitioners who lack specialist training in endocrinology are forced to manage these challenging patient cases.
Mesh Bio, therefore, presents cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region.
It is noted that Mesh Bio’s Health Intelligence Platform, named DARA, provides real-time, multidimensional patient data, which includes health history, lab tests, and medical images.
DARA also delivers a patient-centric visual report, helping doctors counsel patients and allowing patients to understand their laboratory reports and the diseases they live with.
Cited the data, it said DARA provides predictive analytics to identify patients at risk of chronic diseases for earlier diagnosis and treatment.
Moreover, it said DARA enables doctors to leverage knowledge from the global community of healthcare practitioners according to clinical best practices, guidelines, and holistic patient assessments.
“Mesh Bio’s innovative approach and cutting-edge technology could potentially become one of the foundations to provide a better healthcare system for the region,
“We believe that predictive analytics and preventive healthcare can provide many potential benefits for society, and we believe that Mesh Bio will lead this revolution with its digital twin engine,” said Willson Cuaca, Co-Founder and Managing Partner at East Ventures.
Founded in 2009, East Ventures has a platform that provides multi-stage investment, from seed to growth stage investments, for over 300 tech companies across Southeast Asia.
The firm is an early backer of prominent tech companies in the region, such as Tokopedia, Traveloka, Ruangguru, ShopBack, Waresix, Tech in Asia, Xendit, IDN Media, KoinWorks, Sociolla, Kudo (acquired by Grab), Loket (acquired by Gojek), and MokaPOS (acquired by Gojek).